MAPT and type 2 diabetes mellitus: Further studies are needed to explore whether blocking the interaction of tau and IAPP alleviates AD pathology, and to illustrate whether IAPP-tau fibrils can serve as a biomarker for the early diagnosis of AD, especially those with T2DM.